Personalized molecular glue complexes with desired properties

How molecular glue complexes drive targeted protein degradation

Molecular glues are small molecules that bridge a target protein and an E3 ubiquitin ligase receptor, promoting ubiquitination and subsequent degradation by the proteasome. By stabilising otherwise transient or weak protein–protein interfaces, they achieve selective protein depletion without genetic engineering of the target. This mechanism has attracted interest for diseases driven by pathogenic proteins resistant to conventional inhibitors, including certain oncogenic transcription factors and aggregation-prone species in neurodegenerative disorders.

Unlike bifunctional degraders such as PROTACs, molecular glues typically possess a single binding epitope that modulates the surface of the ligase or the target, inducing a novel protein–protein interaction. This results in lower molecular weight, better cell permeability and improved drug-like properties — advantages critical when progressing from tool compounds to clinical candidates. Their ability to act as 'molecular matchmakers' that stabilize transient interactions provides a unique mechanistic advantage over occupancy-dependent inhibitors, particularly for targets lacking deep binding pockets.

Persistent challenges: size, specificity and temporal control

Early molecular glues faced practical hurdles: large degron tags impeded integration into endogenous loci, reducing physiological relevance. Off-target degradation arose when glues promoted interactions with non-target proteins, leading to cytotoxicity. Achieving temporal control required molecules responsive to cellular cues while maintaining stability for therapeutic use.

These limitations underscored the need for personalised molecular glues: compact, high-affinity complexes engineered for a defined target–ligase pair with minimal off-target activity and tunable degradation kinetics. Overcoming these barriers requires not only chemical optimization but also deep understanding of the structural and dynamic basis of ternary complex formation, where subtle changes in interfacial chemistry can dramatically alter selectivity profiles.

PT-179 and the rise of optimised, compact degraders

PT-179, an optimised molecular glue that binds the cereblon E3 ligase receptor without measurable off-target degradation, serves as a versatile scaffold for engineering personalised complexes. Its compact size facilitates knock-in at endogenous loci via CRISPR–Cas9, preserving native expression while enabling controlled degradation.

Discovery combined directed evolution with rational design, iteratively selecting variants for improved affinity and reduced promiscuity. High-throughput screening and computational modelling — increasingly powered by machine learning predicting interaction hotspots — accelerated identification of chemical modifications enhancing efficacy and safety. This integrated approach exemplifies how iterative screening guided by structural insights can yield molecules that balance potency with selectivity, setting a benchmark for next-generation degraders.

Therapeutic opportunities in oncology, neurodegeneration and precision medicine

Personalised molecular glues expand the druggable proteome by targeting proteins traditionally 'undruggable'. In oncology, they can degrade oncogenic transcription factors such as IKZF1/3 or MYC-family proteins, offering a mechanism distinct from kinase inhibition. For neurodegenerative diseases, selectively clearing aggregation-prone proteins like tau or α-synuclein variants without disrupting normal homeostasis is a compelling therapeutic hypothesis.

Personalisation enables tailoring degradation profiles to patient-specific protein isoforms or mutations, aligning with precision medicine where molecular diagnostics guide glue variant selection to an individual's proteomic landscape, potentially improving response and reducing adverse events. This patient-stratified approach could transform treatment paradigms by matching degrader potency to target expression levels and genetic background, minimizing exposure in non-responders while maximizing effect in susceptible populations.

Enabling technologies: structural biology, chemical biology and genome editing

High-resolution structural biology — cryo-electron microscopy and X-ray crystallography — reveals atomic details of glue-mediated ternary complexes, informing rational design. CRISPR–Cas9 allows seamless insertion of compact degrons into endogenous genes, creating physiologically relevant models. Chemical biology platforms, including photoactivatable molecular glues, confer spatiotemporal control over degradation, enhancing therapeutic precision.

Together, these tools create a virtuous cycle: structural insights guide synthesis; genome editing validates relevance; chemical biology probes dynamics; and data feed computational models predicting next-generation optimised glues. For instance, time-resolved crystallography can capture intermediate states of complex formation, while proteome-wide ubiquitin remnant profiling (diGly proteomics) enables unbiased assessment of degradation specificity across the entire proteome.

Future directions: broader target scope, AI integration and combination modalities

The field aims to expand the repertoire of targetable proteins and recruitable E3 ligases. Of ~600 human E3 ligases, only a handful — cereblon, VHL, MDM2, DCAF15 — have been exploited. Broadening this palette unlocks new target classes and tissue selectivities. Multi-omics and AI promise to predict optimal glue candidates for individual proteomes, accelerating design–build–test cycles.

Combination strategies are gaining traction. Pairing molecular glues with immunotherapy — e.g., degrading immune checkpoint regulators — could yield synergistic anti-tumour effects. Integrating glue-mediated degradation with gene editing or RNA therapeutics may enable conditional control of protein networks, opening frontiers in complex disease modulation. Such combinations might allow sequential or concurrent targeting of multiple nodes in disease pathways, potentially overcoming resistance mechanisms that limit monotherapy efficacy.

Ethical, safety and regulatory considerations

Rigorous off-target profiling and long-term safety assessment are non-negotiable. Comprehensive ubiquitinome profiling, proteome-wide degradation assays and chronic toxicity studies must precede clinical translation. Ethical imperatives include equitable access to these advanced therapies and robust informed-consent frameworks for personalised regimens.

Regulatory agencies must adapt frameworks for targeted protein degraders, addressing pharmacodynamic biomarkers, degradation kinetics as a dosing parameter, and implications of irreversible target removal. Early engagement between developers, regulators and patient advocates is essential for responsible innovation. Additionally, considerations around germline versus somatic editing when using CRISPR-based knock-in models, and long-term monitoring for potential neo-antigen formation from novel neo-interfaces, require careful evaluation as these technologies advance toward clinical use.

What this means

Personalised molecular glue complexes represent a paradigm shift in targeted modulation of protein function. By enabling precise, efficient and context-aware degradation of disease-relevant proteins, these engineered molecules hold transformative potential for biotechnology and medicine. Continued interdisciplinary research — integrating structural biology, computational design, chemical biology and genome engineering — will refine molecular glue technology, advancing personalised therapeutics with improved efficacy and safety. As the field matures, addressing ethical, safety and regulatory challenges will be crucial to realising the full benefits of personalised molecular glue complexes for global health.